11. Abirateronehas been shown to:
a. Statistically improveOS inmenwithnon-metastaticCRPCbefore chemotherapy.
b. Statistically improveOS inmenwithmetastaticCRPC after chemotherapy.
c. Improve radiographic progression free survival in in patients with lung and liver metastases prior to
chemotherapy.
d. Improve time toCRPC inpatientswithbiochemical recurrent prostate cancer.
12. Side effects related to themechanismof actionof abiraterone include:
a. Decreased cortisol due to adrenal inhibitionofCYP17A.
b. DecreasedDHEA-Sdue to adrenal inhibitionofCYP17A.
c. Increased cortisol due to feedback effects ofACTH.
d. Decreased aldosteronedue to feedback effects ofACTH
13. Patientswithprostatecancerexperiencedasurvivalbenefitof4.8months treatedwithenzalutamidecompared
toplacebo in theAFFIRM trial. Thesedata reflectwhichpatient population?
a. MenwithmCRPCwhohavediseaseprogressionbutweredocetaxel naïve.
b. MenwithmCRPCwhohaddiseaseprogression following sipuleucel-Tor abiraterone andprednisone.
c. MenwithmCRPCwhohavediseaseprogression followingdocetaxel.
d. MenwithCRPCwitheitherbiochemicalorradiographicdiseaseprogressionwhoaredocetaxelnaïveand
asymptomatic.
14. Theratesofadverseevents in theAFFIRMstudyweresimilarbetween thegroups,despiteasignificantly longer
exposure to enzalutamide and reporting time in the enzalutamide cohort compared toplacebo. Concerning
toxicitieswhichwere specific to enzalutamide in this study includedwhichof the following?
a. SignificantQTprolongation.
b. Seizure.
c. Hepatotoxicity.
d. Metabolic syndrome.
15. Whatwas the improvement inmedianoverall survival forpatients receiving radium223on the randomized
phase IIIALSYMPCA trial?
a. 1.0months.
b. 3.1months.
c. 3.6months.
d. 4.6months.
16. Thepredominant formof decayof radium223 is in the formof:
a. Alphaparticle.
b. Betaparticle.
c. Gamma ray.
d. Photonparticles.
POST-TESTFORCME
A13
©TheCanadian Journal ofUrology™: International Supplement, April 2014
